ovarian
epitheli
cancer
lethal
gynecolog
cancer
western
world
time
initi
diagnosi
patient
present
diseas
spread
beyond
ovari
despit
advanc
surgic
chemotherapeut
approach
patient
advanc
stage
cancer
surviv
year
initi
diagnosi
etiolog
ovarian
carcinogenesi
still
among
less
understood
major
human
malign
gener
accept
ovarian
epitheli
cancer
aris
ovarian
surfac
epithelium
ose
cover
ovari
ose
simpl
rather
primit
mesothelium
epitheli
mesenchym
characterist
contrast
mesothelia
elsewher
ose
retain
properti
rel
uncommit
pluripot
cell
abil
differenti
divers
respons
differ
stimuli
progress
malign
ose
becom
commit
epitheli
phenotyp
mullerian
duct
associ
increas
ecadherin
express
undergo
convers
uniqu
characterist
distinguish
ovarian
cancer
cancer
usual
becom
less
differenti
epithelium
aris
tumorigenesi
lose
ecadherin
express
progress
moreov
ovarian
cancer
metastas
exfoli
small
nodul
cohes
tumor
cell
primari
tumor
periton
caviti
tumor
cell
often
aggreg
form
spheroidlik
structur
subsequ
implant
invad
periton
tissu
ecadherinmedi
adheren
junction
aberr
activ
hedgehog
hh
signal
pathway
recent
report
variou
human
cancer
basal
cell
carcinoma
prostat
cancer
pancreat
cancer
gastrointestin
malign
ovarian
cancer
mammal
three
hh
ligand
protein
sonic
hedgehog
shh
indian
hh
desert
hh
absenc
ligand
pathway
inact
transmembran
protein
receptor
patch
function
tumor
suppressor
inhibit
smoothen
smo
activ
downstream
signal
compon
glimedi
transcript
target
gene
activ
pathway
initi
bind
three
ligand
shh
indian
hh
desert
hh
patch
allevi
patchedmedi
suppress
smo
activ
signal
cascad
lead
transloc
activ
form
gli
zinc
finger
transcript
factor
nucleu
activ
target
gene
express
aberr
activ
hh
pathway
caus
sustain
increas
endogen
express
hh
liganddepend
ligandindepend
mutat
patch
smo
suppressor
fuse
pathway
current
studi
express
prognost
signific
shh
patch
smo
ovarian
cancer
analyz
effect
express
cell
prolifer
apoptosi
invas
propens
differenti
investig
special
interest
ecadherinmedi
morphogen
function
attempt
better
understand
role
hh
pathway
ovarian
cancer
progress
differenti
eighti
case
formalinfix
paraffinembed
primari
epitheli
ovarian
tumor
retriev
depart
patholog
queen
mari
hospit
univers
hong
kong
immunohistochemistri
hematoxylin
eosinstain
section
review
confirm
histopatholog
diagnosi
use
standard
criteria
histolog
tumor
benign
five
serou
eight
mucin
cystadenoma
borderlin
tumor
serou
mucin
carcinoma
serou
mucin
endometrioid
clear
cell
adenocarcinoma
carcinoma
diagnos
stage
stage
ii
stage
iii
stage
iv
accord
intern
feder
gynecolog
obstetr
classif
regard
histolog
differenti
grade
grade
grade
grade
followup
period
rang
month
median
month
snapfrozen
block
ovarian
tumor
includ
eight
serou
adenocarcinoma
nine
endometrioid
adenocarcinoma
five
clear
cell
carcinoma
four
mucin
adenocarcinoma
well
nine
borderlin
tumor
three
serou
six
mucin
two
benign
mucin
tumor
correspond
normal
fallopian
tube
andor
contralater
ovari
use
rna
extract
block
collect
permiss
institut
review
board
prior
rna
extract
hematoxylin
eosinstain
frozen
section
examin
confirm
histolog
diagnosi
puriti
sampl
portion
sampl
consist
least
cancer
use
experi
two
human
ovarian
cancer
cell
line
purchas
american
type
cultur
collect
manassa
va
three
ovarian
cancer
cell
line
two
immort
cell
line
hose
hose
rais
normal
human
ovarian
surfac
epitheli
cell
gener
gift
prof
swtsao
depart
anatomi
univers
hong
kong
five
cancer
cell
line
rais
serou
carcinoma
among
metastat
cell
ascit
cell
line
cultur
mixtur
medium
invitrogen
carlsbad
ca
medium
st
loui
mo
except
maintain
medium
supplement
fetal
bovin
serum
fb
biomeda
foster
citi
ca
incub
carri
air
immunohistochem
studi
carri
serial
paraffinembed
section
complex
method
section
thick
deparaffin
treat
citrat
buffer
ph
min
microwav
oven
except
antigen
retriev
stain
conduct
heat
pressur
cooker
fill
mm
ethylenediaminetetraacet
acid
buffer
ph
min
cool
treat
hydrogen
peroxid
incub
normal
serum
block
nonspecif
bind
primari
polyclon
antibodi
shh
patch
smo
santa
cruz
biotechnolog
santa
cruz
ca
appli
dilut
incub
overnight
secondari
antibodi
shh
rabbit
antigoat
immunoglobulin
patch
smo
goat
antirabbit
appli
min
room
temperatur
peroxid
use
chromogen
section
counterstain
hematoxylin
dehydr
clear
mount
known
posit
prostat
carcinoma
use
posit
control
patch
smo
normal
gastric
mucosa
serv
posit
control
shh
section
process
replac
primari
antibodi
trisbuff
salin
use
neg
control
immunoreact
antibodi
score
accord
intens
stain
none
weak
moder
strong
total
rna
extract
cell
frozen
tissu
use
trizol
invitrogen
firststrand
complementari
dna
synthes
total
rna
oligodt
primer
superscript
iii
revers
transcriptas
kit
invitrogen
accord
manufactur
protocol
primer
inform
summar
tabl
preliminari
experi
conduct
ensur
polymeras
chain
reaction
pcr
condit
logarithm
phase
reaction
set
primer
pcr
optim
ensur
singl
pcr
product
amplifi
product
correspond
pair
present
quantit
realtim
pcr
appli
confirm
semiquantit
revers
transcript
rt
result
express
frozen
tissu
cell
line
well
evalu
messeng
rna
mrna
express
chang
ecadherin
membran
type
matrix
metalloproteinas
vascular
endotheli
growth
factor
vegf
treatment
aminoethylaminocaproyldihydrocinnamoyl
kaad
cyclopamin
transfect
tabl
reaction
includ
complementari
dna
templat
pmoll
forward
revers
primer
sybr
green
mix
biorad
hercul
ca
conduct
use
icycl
detect
system
biorad
pcr
templat
perform
duplic
one
plate
thermal
cycl
condit
compris
initi
denatur
step
min
cycl
min
rel
fold
chang
method
use
determin
rel
quantit
gene
express
compar
ovarian
cancer
cell
line
display
overexpress
treat
kaadcyclopamin
specif
antagonist
smo
final
concentr
cat
toronto
research
chemic
toronto
canada
fb
medium
tomatidin
fb
dulbecco
modifi
eagl
medium
sigma
cat
structur
similar
compound
nonspecif
inhibit
hh
signal
treat
cell
untreat
cell
fb
medium
use
control
inhibit
effect
express
test
quantit
realtim
pcr
kindli
provid
dr
hiroshi
sasaki
riken
center
development
biolog
kobe
japan
gift
prof
swtsao
depart
anatomi
univers
hong
kong
transient
transfect
cell
line
perform
use
genejuic
transfect
reagent
novagen
darmstadt
germani
accord
manufactur
recommend
plasmid
genejuic
mrna
express
confirm
quantit
realtim
transfect
cell
ectop
express
subject
function
analysi
cell
viabil
analysi
cell
treat
drug
transfect
h
bromid
assay
appli
brief
triplic
sampl
treatment
use
format
twenti
microlit
bromid
mgml
phosphatebuff
salin
ad
well
contain
cultur
medium
without
fb
four
hour
later
medium
aspir
dimethyl
sulfoxid
ad
well
nm
absorb
measur
micropl
reader
experi
repeat
least
three
time
triplic
well
data
present
mean
standard
deviat
sd
termin
deoxynucleotidyl
transferasemedi
dutp
nick
end
label
assay
tunel
perform
accord
manufactur
protocol
roch
indianapoli
brief
cell
fix
paraformaldehyd
room
temperatur
h
permeat
triton
sodium
citrat
freshli
prepar
ice
min
wash
phosphatebuff
salin
sampl
incub
tunel
reaction
mixtur
min
tunel
label
solut
without
enzym
use
neg
control
tunelposit
cell
count
fluoresc
microscop
count
repeat
three
time
percentag
count
calcul
invas
assay
perform
biocoat
matrigel
invas
chamber
bd
bioscienc
san
jose
ca
accord
manufactur
instruct
blockad
pathway
cell
serumfre
medium
without
kaadcyclopamin
treatment
drug
h
plate
onto
matrigelco
filter
transient
transfect
cell
transfect
h
plate
onto
matrigelco
filter
cell
transfect
empti
vector
untransfect
cell
use
control
cell
invad
matrigel
stain
crystal
violet
solut
count
experi
done
triplic
repeat
twice
mean
valu
sd
present
cell
line
use
experi
sinc
treatment
kaadcyclopamin
either
untreat
cell
tomatidinetr
cell
kaadcyclopaminetr
cell
unabl
cross
matrigel
barrier
despit
repeat
attempt
document
studi
cell
seed
plate
allow
grow
confluenc
similars
wound
introduc
monolay
cell
use
steril
yellow
pipett
tip
wound
monolay
cell
wash
three
time
phosphatebuff
salin
remov
cell
debri
cultur
without
kaadcyclopamin
ectop
overexpress
group
cell
transfect
empti
vector
wound
introduc
speed
wound
heal
monitor
photograph
everi
h
use
phase
contrast
microscop
complet
wound
heal
observ
untreat
control
cell
per
well
plate
cultur
plate
allow
grow
overnight
ectop
overexpress
assay
ecadherin
promot
contain
differ
length
ecadherin
promot
prltkluc
intern
control
cotransfect
empti
vector
use
genejuic
transfect
reagent
novagen
lyse
h
inhibit
assay
h
transfect
ecadherin
promot
prltkluc
cell
treat
without
kaadcyclopamin
lyse
h
luciferas
activ
assay
use
dual
luciferas
report
assay
system
procedur
describ
manufactur
promega
madison
wi
percentag
decreas
luciferas
activ
treat
cell
calcul
refer
untreat
control
experi
repeat
least
twice
triplic
well
data
point
repres
mean
sd
total
cell
lysat
cell
line
prepar
sodium
dodecyl
sulfat
lysi
buffer
contain
proteinas
inhibitor
protein
concentr
determin
use
protein
assay
kit
biorad
accord
manufactur
instruct
quantifi
protein
lysat
separ
sodium
dodecyl
gel
electrophoret
transfer
polyvinyliden
difluorid
membran
amersham
bioscienc
piscataway
nj
membran
blot
nonfat
milk
wash
probe
patch
vimentin
santa
cruz
biotechnolog
calretinin
zyme
south
san
francisco
ca
snail
abgent
san
diego
ca
ecadherin
bd
transduct
laboratori
lexington
ky
cytokeratin
sigmaaldrich
well
total
cleav
form
caspas
poli
adpribos
polymeras
parp
cell
signal
danver
wash
membran
incub
horseradish
peroxidaseconjug
antimous
rabbit
goat
antibodi
santa
cruz
biotechnolog
detect
enhanc
chemiluminesc
plu
system
amersham
bioscienc
test
utest
use
assess
differ
immunohistochem
stain
level
among
differ
group
comparison
frequenc
high
express
hh
molecul
differ
clinicopatholog
featur
perform
chisquar
fisher
exact
test
spearman
rank
correl
appli
determin
whether
posit
neg
correl
among
stain
hh
molecul
logrank
test
cox
regress
analysi
appli
evalu
signific
predictor
patient
surviv
cumul
surviv
also
analyz
method
result
obtain
multipl
vitro
experi
report
mean
sd
analyz
twotail
student
ttest
differ
consid
signific
p
analys
perform
use
spss
chicago
il
repres
profil
immunostain
shh
patch
smo
shown
figur
patch
smo
express
observ
cytoplasm
neoplast
epithelium
wherea
shh
present
cytoplasm
stroma
glandular
lumen
tumor
express
mainli
detect
cytoplasm
scatter
nuclear
stain
observ
ovarian
cancer
cell
express
shh
protein
express
present
almost
tumor
differ
level
highest
express
cancer
group
patch
smo
express
observ
benign
mucin
tumor
express
weakli
benign
serou
tumor
mean
express
level
hh
molecul
benign
borderlin
malign
tumor
associ
differ
histolog
type
grade
clinic
stage
shown
supplementari
tabl
avail
carcinogenesi
onlin
immunoreact
patch
smo
borderlin
tumor
increas
howev
signific
differ
protein
express
found
borderlin
malign
tumor
p
utest
wherea
cancer
case
patch
express
patch
express
high
cancer
posit
correl
patch
express
smo
express
ovarian
cancer
p
spearman
rank
correl
express
weak
benign
mucinousser
tumor
increas
borderlin
mucinousser
tumor
heterogen
express
pattern
cancer
group
observ
high
express
observ
frequent
serou
carcinoma
nonser
carcinoma
p
chisquar
express
significantli
correl
patch
p
smo
p
express
ovarian
cancer
spearman
rank
correl
express
patch
significantli
correl
patient
surviv
logrank
analysi
patient
ovarian
cancer
high
express
n
shorter
overal
surviv
month
confid
interv
ci
patient
cancer
lower
express
n
month
ci
p
figur
similarli
patient
high
express
patch
n
also
poorer
surviv
month
ci
lower
patch
express
n
month
ci
p
express
also
relat
diseasefre
surviv
p
cox
regress
analysi
show
patch
independ
prognost
factor
adjust
tumor
grade
stage
histolog
type
patient
age
p
ci
besid
tumor
grade
stage
histolog
type
serousnonser
anoth
three
independ
indic
poor
prognosi
p
p
p
respect
signific
correl
express
shh
patch
smo
tumor
grade
clinic
stage
found
p
chisquar
clinic
sampl
shh
found
frequent
express
hh
ligand
mrna
level
ovarian
cancer
figur
elev
express
shh
mrna
observ
ovarian
cancer
wherea
express
weak
undetect
normal
tissu
benign
borderlin
tumor
p
chisquar
elev
shh
mrna
express
detect
frequent
endometrioid
clear
cell
carcinoma
compar
serou
mucin
carcinoma
p
chisquar
sustain
express
patch
mrna
observ
cancer
sampl
heterogen
mrna
present
ovarian
cancer
confirm
realtim
pcr
compar
normal
counterpart
elev
mrna
express
present
ovarian
cancer
consist
result
clinic
sampl
elev
express
shh
observ
one
five
ovarian
serou
cancer
cell
line
wherea
patch
consist
express
mrna
protein
level
immort
ovarian
epitheli
cell
cancer
cell
variabl
level
figur
semiquantit
realtim
pcr
western
blot
show
significantli
elev
mrna
protein
express
four
five
ovarian
cancer
cell
line
compar
immort
human
ovarian
epitheli
cell
line
hose
hose
figur
shown
figur
express
mesotheli
marker
calretinin
mesenchym
marker
vimentin
evid
normal
ovarian
epitheli
cell
line
hose
hose
wherea
epitheli
marker
ecadherin
detect
cancer
cell
epitheli
marker
cytokeratin
express
present
five
cancer
cell
line
hose
express
snail
transcript
repressor
ecadherin
observ
normal
cancer
cell
line
express
pattern
concur
current
understand
normal
ovarian
epitheli
cell
mesotheli
origin
epitheli
mesenchym
characterist
realtim
pcr
show
mrna
express
level
increas
fold
transfect
ovarian
cancer
cell
supplementari
figur
avail
carcinogenesi
onlin
introduct
cancer
cell
promot
increas
cell
growth
figur
significantli
increas
cell
invas
abil
matrigel
assay
compar
empti
vector
control
untransfect
cell
figur
transfect
migrat
rate
cancer
cell
higher
empti
vector
control
untransfect
cell
figur
protein
express
integrin
total
cleav
form
parp
caspas
figur
increas
ectop
overexpress
associ
upregul
mrna
express
vegf
cancer
cell
figur
ectop
transfect
induc
significantli
increas
express
mesenchym
marker
vimentin
cell
well
slightli
increas
snail
express
importantli
increas
rather
decreas
express
epitheli
marker
ecadherin
observ
figur
significantli
increas
mrna
express
ecadherin
demonstr
realtim
pcr
associ
ectop
overexpress
figur
examin
whether
ectop
express
activ
ecadherin
transcript
ecadherin
promot
report
construct
contain
bp
ecad
bp
ecad
bp
ecad
bp
ecad
flank
region
promot
cotransfect
cell
dual
luciferas
assay
cancer
cell
show
ecadherin
promot
activ
upregul
transcript
level
compar
empti
vector
control
figur
mrna
express
decreas
ovarian
cancer
cell
treatment
kaadcyclopamin
supplementari
figur
avail
carcinogenesi
onlin
cell
prolifer
suppress
three
cancer
cell
line
compar
control
tomatidin
control
untreat
control
figur
addit
obvious
increas
apoptosi
assess
tunel
assay
observ
cell
treatment
figur
wherea
show
signific
chang
decreas
protein
express
total
form
prap
well
increas
express
cleav
caspas
parp
cancer
cell
inhibit
pathway
observ
suggest
death
receptor
pathway
involv
apoptosi
induc
block
hh
pathway
figur
matrigel
invas
assay
shown
figur
kaadcyclopaminetr
cell
show
much
lower
invas
abil
compar
tomatidinetr
control
untreat
cell
evidenc
decreas
number
cell
migrat
matrigel
suppress
effect
kaadcyclopamin
treatment
cancer
cell
mobil
also
note
woundheal
assay
figur
associ
decreas
mrna
express
vegf
figur
decreas
protein
express
integrin
figur
respons
kaadcyclopamin
treatment
morpholog
cell
chang
cohes
sheet
roundish
epithelioid
cell
scatter
small
primit
cell
figur
growth
inhibit
vitro
result
decreas
ecadherin
cytokeratin
snail
calretinin
protein
express
figur
indic
inhibit
pathway
induc
dedifferenti
chang
ovarian
cancer
cell
primitivelik
cell
rather
transit
report
human
cancer
quantit
realtim
pcr
confirm
kaadcyclopamin
block
signific
downregul
ecadherin
transcript
concur
downregul
target
gene
mrna
figur
furthermor
ecadherin
promot
activ
decreas
compar
tomatidinetr
control
figur
suggest
ecadherin
activ
inactiv
transcript
level
inhibit
pathway
result
suggest
inhibit
hh
pathway
induc
dedifferenti
regress
chang
ovarian
cancer
cell
primit
pleuripotenti
ovarian
epithelium
lack
epitheli
characterist
hh
signal
pathway
control
mani
aspect
tissu
pattern
cell
prolifer
differenti
variou
organ
normal
develop
adult
pathway
remain
activ
number
stem
cell
regener
tissu
aberr
activ
pathway
report
varieti
human
cancer
studi
hh
pathway
ovarian
cancer
scanti
current
studi
besid
confirm
increas
express
shh
patch
smo
protein
borderlin
tumor
compar
benign
ovarian
tumor
report
chen
et
al
also
document
heterogen
mrna
protein
express
pattern
cancer
group
importantli
associ
patch
protein
overexpress
poor
surviv
ovarian
cancer
patient
demonstr
first
time
predict
associ
poor
surviv
particular
independ
clinicopatholog
paramet
report
hh
signal
pathway
relat
cancer
cell
mobil
migrat
invas
sever
type
cancer
probabl
directli
particip
cell
migrat
angiogenesi
process
studi
correl
overexpress
poor
surviv
explain
cell
prolifer
migrat
invas
angiogenesispromot
effect
apoptosisinhibit
effect
overexpress
chang
associ
increas
express
vegf
integrin
play
critic
role
ovarian
carcinogenesi
critic
determin
matrix
degrad
invas
ovarian
cancer
cell
wherea
integrin
play
import
role
metastat
process
particip
contact
interact
larg
varieti
extracellular
matrix
protein
vegf
thought
contribut
ovarian
tumor
progress
stimul
angiogenesi
promot
ascit
accumul
increas
permeabl
diaphragmat
tumorassoci
vasculatur
overexpress
cancer
cell
also
induc
increas
express
known
antiapoptot
gene
import
chemotherapyresist
factor
overexpress
may
result
accumul
cell
phase
cell
cycl
divis
contribut
chemoresist
thu
aberr
activ
hh
may
result
cancer
cell
resist
apoptosi
particip
death
receptor
pathway
ectop
express
may
also
facilit
spread
ovarian
cancer
cell
increas
express
ecadherin
associ
overexpress
may
facilit
attach
among
tumor
cell
form
aggreg
spheroid
tumor
cell
adher
invad
periton
mesotheli
line
thu
contribut
abil
colon
new
site
result
transcoelom
spread
ovarian
cancer
periton
ovarian
cancer
spheroid
shown
protect
apoptosi
induc
radiat
therapeut
drug
coexist
overexpress
vimentin
consid
acceler
cancer
cell
invas
breast
cancer
mechan
differenti
contribut
aggress
clinic
behavior
ovarian
cancer
overexpress
inhibit
pathway
kaadcyclopamin
suppress
cell
prolifer
induc
apoptosi
vitro
repress
cell
growth
may
due
induct
apoptosi
demonstr
studi
induct
cell
cycl
arrest
report
recent
variabl
sensit
kaadcyclopamin
treatment
observ
known
increas
express
antiapoptot
gene
caus
resist
chemotherapeut
drug
radiat
therapi
wherea
decreas
may
promot
apoptot
respons
anticanc
drug
even
though
increas
express
cleav
form
caspas
parp
observ
cell
quit
resist
regard
effect
cancer
cell
apoptosi
probabl
due
high
express
genet
alter
despit
elev
express
cell
line
cell
line
sensit
kaadcyclopamineinduc
apoptosi
cell
growth
inhibit
natur
sensit
may
relat
low
express
also
found
blockad
hh
pathway
inhibit
ovarian
cancer
invas
motil
vitro
associ
decreas
express
integrin
vegf
moreov
inhibit
induc
dedifferenti
cancer
cell
primit
state
kaadcyclopamin
treatment
cell
morpholog
chang
tightli
pack
roundish
appear
scatter
small
primitivelik
phenotyp
decreas
express
ecadherin
cytokeratin
snail
vimentin
calretinin
observ
find
differ
transit
observ
pancreat
cancer
cell
treatment
instead
chang
may
reflect
regress
primit
pluripot
phenotyp
decreas
express
ecadherin
may
inhibit
ovarian
cell
invas
disrupt
adher
junction
prevent
spheroid
morphogenesi
thu
prevent
attach
peritoneum
downregul
ecadherin
frequent
document
transit
tumor
progress
domin
transcript
repress
mainli
respons
loss
ecadherin
express
breast
cancer
transcript
factor
snail
one
repressor
ecadherin
gene
express
turn
control
transit
snail
also
earli
gene
skin
directli
induc
snail
transcript
induct
condit
transgen
basal
keratinocyt
mous
skin
led
rapid
upregul
snail
transcript
cell
prolifer
interfollicular
epidermi
establish
skin
lesion
exhibit
molecular
similar
basal
cell
carcinoma
includ
loss
ecadherin
express
mediat
snail
howev
current
studi
ecadherin
express
ovarian
cancer
cell
line
instead
normal
epitheli
cell
line
wherea
snail
express
present
cancer
normal
cell
line
without
big
differ
treatment
kaadcyclopamin
decreas
express
ecadherin
observ
associ
decreas
rather
increas
snail
express
cell
convers
ectop
overexpress
cell
induc
increas
express
ecadherin
wherea
signific
chang
snail
express
found
suggest
ecadherin
express
ovarian
cancer
may
regul
snailindepend
mechan
demonstr
regul
ecadherin
express
chang
transcript
level
sinc
sequencespecif
dna
bind
protein
interact
motif
bind
site
within
bp
ecadherin
promot
downregul
ecadherin
transcript
activ
may
due
indirect
effect
express
possibl
activ
repressor
transfect
shorter
promot
construct
associ
increas
activ
wherea
longer
respons
possibl
transcript
repressor
bind
site
locat
upstream
proxim
ecadherin
promot
element
increas
express
ecadherin
might
also
mediat
demethyl
cpg
dinucleotid
ecadherin
promot
studi
need
explor
underli
mechan
conclus
show
first
time
overexpress
patch
correl
poor
clinic
outcom
ovarian
cancer
overexpress
increas
cancer
cell
aggress
upregul
express
vegf
antiapoptot
differenti
chang
find
provid
molecular
basi
role
hh
pathway
ovarian
cancer
suggest
inhibit
hh
pathway
kaadcyclopamin
may
valid
therapeut
strategi
ovarian
cancer
supplementari
tabl
supplementari
data
found
http
carcinoxfordjournalsorg
univers
hong
kong
confer
research
committe
grant
